Listed pharmaceutical companies' R&D innovation competes with Yifan Pharmaceutical's performance
Time:2019-03-04
[China Pharmaceutical Network Enterprise News] At the 2017 China Pharmaceutical Entrepreneur Scientists Investors Conference held on the shore of Yanqi Lake in Beijing on September 23, Yifan Pharmaceutical was “competitive” and “research and innovation” in listed pharmaceutical companies with high gold content. Both of them competed successfully. It is reported that this is the first time that Yifan Pharmaceutical has entered the above list.
As one of the most important events in the domestic pharmaceutical industry, this year's conference will analyze more than 300 Chinese pharmaceutical companies with annual sales of more than 100 million yuan in China, Singapore, New York, etc., and conduct comprehensive evaluation through the industrial dimension of enterprises. According to the selection list, Hengrui Medicine, Dong'e Ejiao and Yunnan Baiyao were successfully selected as “Top 20 Competitiveness of Chinese Pharmaceutical Listed Companies”; Hengrui Medicine, Fosun Pharma and Shanghai Pharmaceuticals, etc. Innovative pharmaceutical listed companies in the top ten." It is worth noting that, together with the above-mentioned well-known pharmaceutical companies, this award also includes the “star stock” of the recent capital market – Yifan Medicine.
This is the first time that Yifan Pharmaceutical has been included in the above list. According to iFind statistics, Yifan Pharmaceutical ranked 21st in the nearly 100 chemical and pharmaceutical industries of A shares with a net profit of 460 million yuan in the first half of the year. The continuous improvement of the performance has laid a solid economic foundation for the company's R&D and innovation. At present, there are 24 research projects in Yifan Pharmaceutical Reserve, more than 100 patent applications, including nearly 40 international patents, and become the first innovative biopharmaceutical in China. The United States entered the Chinese enterprises in Phase II and Phase III clinical trials. At the same time, the company also has a number of major projects in the development of new products for the development of new drugs to create major science and technology projects, the province's scientific and technological achievements transformation projects.
According to the medium and long-term development plan of Yifan Pharmaceutical, we will adhere to the goal of “integration, innovation and internationalization” and continue to develop pharmaceutical preparations and APIs as the main industries. On the basis of maintaining the original business, especially the quality business, we will continue to intensify innovation, promote the healthy and rapid development of the company, and continuously enhance the company's value.
